Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: An exploratory trial

Psychological Medicine

Volumn 42, Issue 5, 2012, Pages 1049-1056

  Morrison, A P ^a,b   Hutton, P ^b   Wardle, M ^b   Spencer, H ^b,d   Barratt, S ^b   Brabban, A ^e,f   Callcott, P ^c   Christodoulides, T ^c   Dudley, R ^c,d   French, P ^b   Lumley, V ^e   Tai, S J ^a   Turkington, D ^c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e The Royal College of Psychiatrists   (United Kingdom)

^f DURHAM UNIVERSITY   (United Kingdom)

Author keywords

Antipsychotic medication; cognitive therapy; psychosis; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TREATMENT REFUSAL; YOUNG ADULT;

EID: 82955185134     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291711001899     Document Type: Article

References (37)

1. Beck AT (1976). Cognitive Therapy and the Emotional Disorders. International Universities Press: New York.
2. Christodoulides T, Dudley R, Brown S, Turkington D, Beck AT (2008). Cognitive behaviour therapy in patients with schizophrenia who are not prescribed antipsychotic medication: a case series. Psychology and Psychotherapy: Theory, Research and Practice 81, 199-207. (Pubitemid 351951405)
3. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates: Hillsdale, NJ.
4. Haddock G, McCarron J, Tarrier N, Faragher EB (1999). Scales to measure dimensions of hallucinations and delusions: the Psychotic Symptoms Rating Scales (PSYRATS). Psychological Medicine 29, 879-889. (Pubitemid 29381048)
5. Hamer RM, Simpson PM (2009). Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. American Journal of Psychiatry 166, 639-641.
6. Ho B-C, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Archives of General Psychiatry 68, 128-137.
7. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276. (Pubitemid 18039085)
8. Kay SR, Opler LA, Fiszbein A (1988). Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Research 23, 276-286.
9. Kingdon D, Turkington D (2005). Cognitive Therapy for Schizophrenia. Guilford Press: New York.
10. Lacro JP, Dunn LB, Dolder CR (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 63, 892-909. (Pubitemid 35231730)
11. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41.
12. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR (2006). Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31, 2318-2325. (Pubitemid 44413213)
13. Leucht S, Kissling W, Davis JM (2010). The PANSS should be rescaled. Schizophrenia Bulletin 36, 461-462.
14. Lieberman JA, Stroup TS, McEvoy JP, Swartz M, Rosenheck R, Perkins D, Keefe RS, Davis S, Davis C, Lebowitz B, Severe JB, Hsiao JK (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223. (Pubitemid 41345943)
15. Lynch D, Laws KR, McKenna PJ (2010). Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychological Medicine 40, 9-24.
16. Moncrieff J, Cohen D, Mason JP (2009). The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatrica Scandinavica 120, 102-111.
17. Moncrieff J, Leo J (2010). A systematic review of the effects of antipsychotic drugs on brain volume. Psychological Medicine 40, 1409-1422.
18. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 101, 323-329. (Pubitemid 30173584)
19. Morrison AP (1994). Cognitive behaviour therapy for auditory hallucinations without concurrent medication: a single case. Behavioural and Cognitive Psychotherapy 22, 259-264. (Pubitemid 24269096)
20. Morrison AP (2001a). Cognitive therapy for auditory hallucinations as an alternative to antipsychotic medication: a case series. Clinical Psychology and Psychotherapy 8, 136-147. (Pubitemid 33696281)
21. Morrison AP (2001b). The interpretation of intrusions in psychosis: an integrative cognitive approach to hallucinations and delusions. Behavioural and Cognitive Psychotherapy 29, 257-276. (Pubitemid 32666758)
22. Morrison AP, Barratt S (2010). What are the components of CBT for psychosis? A Delphi study. Schizophrenia Bulletin 36, 136-142.
23. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP (2004a). Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. British Journal of Psychiatry 185, 291-297. (Pubitemid 39331330)
24. Morrison AP, Renton JC, Dunn H, Williams S, Bentall RP (2004b). Cognitive Therapy for Psychosis: A Formulation-based Approach. Brunner-Routledge: London.
25. MRC (2000). A Framework for Development and Evaluation of RCTs for Complex Interventions to Improve Health. Medical Research Council: London.
26. Neil ST, Kilbride M, Pitt L, Welford M, Nothard S, Sellwood W, Morrison AP (2009). The Questionnaire about the Process of Recovery (QPR): a research instrument developed in collaboration with service users. Psychosis 1, 145-155.
27. NICE (2009). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. National Institute for Clinical Excellence: UK.
28. Owens GS, Richardson G, David AS, Szmukler G, Hayward P, Hotopf M (2008). Mental capacity to make decisions on treatment in people admitted to psychiatric hospitals: cross sectional study. British Medical Journal 337, 448.
29. Perkins DO (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 63, 1121-1128. (Pubitemid 36084056)
30. Pilling S, Bebbington PE, Kuipers E, Garety PA, Geddes J, Orbach G, Morgan C (2002). Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine 32, 763-782. (Pubitemid 34823330)
31. Ray WA, Chung CP, Murray KT, Hall K, Stein M (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 360, 225-235.
32. Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR (2011). Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. American Journal of Psychiatry 168, 286-292.
33. Tam C, Law S (2007). Best practices: a systematic approach to the management of patients who refuse medications in an assertive community treatment team setting. Psychiatric Services 58, 457-459. (Pubitemid 46640634)
34. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor Jr. JJ, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ (2008). World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research 100, 20-38.
35. Villeneuve K, Potvin S, Lesage A, Nicole L (2010). Meta-analysis of rates of drop-out from psychosocial treatment among persons with schizophrenia spectrum disorder. Schizophrenia Research 121, 266-270.
36. Warner L, Mariathasan J, Lawton-Smith S, Samele C (2006). A Review of the Literature and Consultation on Choice and Decision-Making for Users and Carers of Mental Health and Social Care Services. King's Fund/Sainsbury Centre for Mental Health: London.
37. Wykes T, Steel C, Everitt B, Tarrier N (2008). Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophrenia Bulletin 34, 523-537.